



21st October 2008

**Metoject ® for the treatment of moderate to severe
rheumatoid arthritis.**

The New Therapies Subgroup discussed the above drug at a meeting on the 21st October 2008. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Metoject ® for the treatment of moderate to severe rheumatoid arthritis.

The group recommends that Metoject ® may be considered as a treatment option for patients in whom parenteral methotrexate is indicated. Prior to any home treatment with parenteral methotrexate being initiated there must be a clear protocol in place that defines who is responsible for blood monitoring of therapy.

Metoject is currently more expensive than use of in-house manufactured methotrexate injections however this product is unlicensed. Commissioners may wish to discuss the most cost effective method of providing this service with their local provider.

Review date: October 2010

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.